283 related articles for article (PubMed ID: 32946432)
1. TNNC1 Reduced Gemcitabine Sensitivity of Nonsmall-Cell Lung Cancer by Increasing Autophagy.
Ye X; Xie G; Liu Z; Tang J; Cui M; Wang C; Guo C; Tang J
Med Sci Monit; 2020 Sep; 26():e922703. PubMed ID: 32946432
[TBL] [Abstract][Full Text] [Related]
2. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.
Chen W; Tan X; Yang Q; Fang Z; Xu Y
Cell Signal; 2022 Jun; 94():110326. PubMed ID: 35367362
[TBL] [Abstract][Full Text] [Related]
3. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
4. FOXO3/TRIM22 axis abated the antitumor effect of gemcitabine in non-small cell lung cancer via autophagy induction.
Wang Y; Liang HX; Zhang CM; Zou M; Zou BB; Wei W; Hu W
Transl Cancer Res; 2020 Feb; 9(2):937-948. PubMed ID: 35117439
[TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibitor of Notch‑3 enhances the sensitivity of NSCLC cells to gemcitabine.
Hu BD; Guo J; Ye YZ; Du T; Cheng CS; Jiang Q; Liu RN; Zhang YB
Oncol Rep; 2018 Jul; 40(1):155-164. PubMed ID: 29781034
[TBL] [Abstract][Full Text] [Related]
7. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
Oguri T; Achiwa H; Sato S; Bessho Y; Takano Y; Miyazaki M; Muramatsu H; Maeda H; Niimi T; Ueda R
Mol Cancer Ther; 2006 Jul; 5(7):1800-6. PubMed ID: 16891466
[TBL] [Abstract][Full Text] [Related]
8. Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A.
Bian WG; Zhou XN; Song S; Chen HT; Shen Y; Chen P
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):649-659. PubMed ID: 30720173
[TBL] [Abstract][Full Text] [Related]
9. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
Hatami E; Nagesh PKB; Jaggi M; Chauhan SC; Yallapu MM
Eur J Pharmacol; 2020 Dec; 888():173486. PubMed ID: 32805254
[TBL] [Abstract][Full Text] [Related]
10. LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy.
Huang FX; Chen HJ; Zheng FX; Gao ZY; Sun PF; Peng Q; Liu Y; Deng X; Huang YH; Zhao C; Miao LJ
Int J Oncol; 2019 Jan; 54(1):339-347. PubMed ID: 30387831
[TBL] [Abstract][Full Text] [Related]
11. Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer.
Qu Y; Yang Y; Liu B; Xiao W
Med Oncol; 2010 Dec; 27(4):1303-8. PubMed ID: 20012234
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
13. CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 Phosphorylation.
Zhao Z; Li J; Jiang Y; Xu W; Li X; Jing W
Med Sci Monit; 2017 Jun; 23():2906-2916. PubMed ID: 28614291
[TBL] [Abstract][Full Text] [Related]
14. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells.
Ikeda R; Vermeulen LC; Lau E; Jiang Z; Sachidanandam K; Yamada K; Kolesar JM
Int J Oncol; 2011 Feb; 38(2):513-9. PubMed ID: 21152861
[TBL] [Abstract][Full Text] [Related]
16. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
[TBL] [Abstract][Full Text] [Related]
17. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2.
Wang Y; Li F; Ma D; Gao Y; Li R; Gao Y
Mol Med Rep; 2019 Oct; 20(4):3519-3526. PubMed ID: 31485614
[TBL] [Abstract][Full Text] [Related]
20. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
Zhou J; Zhang L; Zheng H; Ge W; Huang Y; Yan Y; Zhou X; Zhu W; Kong Y; Ding Y; Wang W
Cancer Med; 2020 Feb; 9(3):1115-1130. PubMed ID: 31823522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
